Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.69 |
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.69 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373958 | 1.00 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL3868448 | 0.92 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL483282 | 0.90 | TLR7 (0.60) | TLR7TLR8NUDT1 | |
| SCHEMBL30346099 | 0.90 | TLR7 (0.60) | TLR7TLR8NUDT1 | |
| SCHEMBL3862191 | 0.90 | TLR7 (0.80) | TLR7TLR8NUDT1 | |
| SCHEMBL3865767 | 0.90 | TLR7 (0.80) | TLR7TLR8NUDT1 | |
| SCHEMBL29374507 | 0.89 | TLR7 (0.73) | TLR7TLR8NUDT1 | |
| SCHEMBL3862520 | 0.89 | TLR7 (0.73) | TLR7TLR8NUDT1 | |
| SCHEMBL3867919 | 0.89 | TLR7 (0.61) | TLR7TLR8NUDT1 | |
| SCHEMBL1689229 | 0.88 | TLR7 (0.52) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | claimed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | claimed |
| EP-4148069-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2023-03-15 | — | — | EP | claimed |
| CN-115554406-A | anti-CD 20 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-115350279-A | anti-HER 2 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-115252792-A | anti-EGFR combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-4056594-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | Birdie Biopharmaceuticals Inc. (KY) | 2022-09-14 | — | — | EP | claimed |
| US-20220175762-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2022-06-09 | — | — | US | claimed |
| EP-4001311-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2022-05-25 | — | — | EP | claimed |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2018-04-26 | — | — | US | claimed |
| US-9827329-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-11-28 | — | — | US | claimed |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-10-12 | — | — | US | claimed |
| US-20170114137-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-04-27 | — | — | US | claimed |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2017-03-02 | — | — | US | claimed |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2017-02-02 | — | — | US | claimed |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2016-12-29 | — | — | US | claimed |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-11-10 | — | — | US | claimed |
| EP-1651190-B1 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2012-09-19 | — | — | EP | claimed |
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114137-A1 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | PDCD1LG2, CD274, PDCD1 | TLR7 879/4885TLR8 585/4885NUDT1 3947/4885 |
| US-20180110874-A1 | Compounds and Compositions for Immunotherapy | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885NUDT1 2607/4885 |
| US-20170056391-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | TP53, MCL1, MSH2 | TLR7 1537/4885TLR8 2076/4885NUDT1 1375/4885 |
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | IFNG, IRF3, ICOS | TLR7 18/4885TLR8 28/4885NUDT1 1398/4885 |
| US-20170028079-A1 | Compounds and Compositions for Treating HER2 Positive Tumors | ERBB2, EGFR, TP53 | TLR7 362/4885TLR8 249/4885NUDT1 4309/4885 |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | EGFR, ERBB3, ERBB2 | TLR7 2007/4885TLR8 1153/4885NUDT1 3504/4885 |
| US-20220175762-A1 | IMMUNE MODULATORY COMPOSITIONS AND METHODS FOR TREATING CANCERS | IFNG, CD47, CD74 | TLR7 75/4885TLR8 61/4885NUDT1 3300/4885 |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | CD47, TP53, CD74 | TLR7 198/4885TLR8 159/4885NUDT1 3366/4885 |
| US-20160375148-A1 | Compounds and Compositions for Treating EGFR Expressing Tumors | EGFR, ERBB2, ERBB3 | TLR7 634/4885TLR8 518/4885NUDT1 4361/4885 |
| US-20170290923-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TLR7 980/4885TLR8 901/4885NUDT1 4518/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885NUDT1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.